Limits...
Phase I study of olaratumab in Japanese patients with advanced solid tumors.

Doi T, Ma Y, Dontabhaktuni A, Nippgen C, Nippgen J, Ohtsu A - Cancer Sci. (2014)

Bottom Line: The most common olaratumab-related treatment-emergent adverse events (TEAEs) were proteinuria (25.0%) and elevated aspartate transaminase (12.5%).One patient (cohort 2) had two olaratumab-related Grade 3 TEAEs (increased aspartate aminotransferase and tumor hemorrhage); otherwise, olaratumab-related TEAEs were Grade 1/2.Seven patients (43.8%) had a best response of stable disease.

View Article: PubMed Central - PubMed

Affiliation: National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Show MeSH

Related in: MedlinePlus

Time on treatment. The duration of treatment for each patient is shown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317910&req=5

fig01: Time on treatment. The duration of treatment for each patient is shown.

Mentions: Of the seven patients with a best response of SD, two patients in cohort 3 experienced disease stabilization >4 months; these patients had hypopharyngeal cancer (4.2 months) and leiomyosarcoma of inferior vena cava origin (5.6 months). The others experienced disease stabilization that lasted approximately 2.8 months each. Figure 1 shows time on treatment for each patient.


Phase I study of olaratumab in Japanese patients with advanced solid tumors.

Doi T, Ma Y, Dontabhaktuni A, Nippgen C, Nippgen J, Ohtsu A - Cancer Sci. (2014)

Time on treatment. The duration of treatment for each patient is shown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317910&req=5

fig01: Time on treatment. The duration of treatment for each patient is shown.
Mentions: Of the seven patients with a best response of SD, two patients in cohort 3 experienced disease stabilization >4 months; these patients had hypopharyngeal cancer (4.2 months) and leiomyosarcoma of inferior vena cava origin (5.6 months). The others experienced disease stabilization that lasted approximately 2.8 months each. Figure 1 shows time on treatment for each patient.

Bottom Line: The most common olaratumab-related treatment-emergent adverse events (TEAEs) were proteinuria (25.0%) and elevated aspartate transaminase (12.5%).One patient (cohort 2) had two olaratumab-related Grade 3 TEAEs (increased aspartate aminotransferase and tumor hemorrhage); otherwise, olaratumab-related TEAEs were Grade 1/2.Seven patients (43.8%) had a best response of stable disease.

View Article: PubMed Central - PubMed

Affiliation: National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Show MeSH
Related in: MedlinePlus